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Abstract
Background: Epidemiological and molecular findings suggest a relationship between Alzheimer’s disease (AD) and
dyslipidemia, although the nature of this association is not well understood.
Results: Using linear mixed effects models, we investigated the relationship between CSF levels of heart fatty acid
binding protein (HFABP), a lipid binding protein involved with fatty acid metabolism and lipid transport, amyloid-β
(Aβ), phospho-tau, and longitudinal MRI-based measures of brain atrophy among 295 non-demented and
demented older individuals. Across all participants, we found a significant association of CSF HFABP with
longitudinal atrophy of the entorhinal cortex and other AD-vulnerable neuroanatomic regions. However, we found
that the relationship between CSF HABP and brain atrophy was significant only among those with low CSF Aβ1–42
and occurred irrespective of phospho-tau181p status.
Conclusions: Our findings indicate that Aβ-associated volume loss occurs in the presence of elevated HFABP
irrespective of phospho-tau. This implicates a potentially important role for fatty acid binding proteins in
Alzheimer’s disease neurodegeneration.
Keywords: Alzheimer’s disease, Fatty acids, Lipids, Amyloid, Tau, Brain atrophy
Background
A growing number of epidemiological and experimental
studies suggest an association between Alzheimer’s disease
(AD) and dyslipidemia. In observational studies, high serum
cholesterol levels have been associated with increased risk
of AD [1,2]. Genetic linkage and genome-wide association
studies have identified a number of genes involved with
cholesterol metabolism and transport as AD susceptibility
loci [3,4] and cellular and molecular biology research has
indicated a critical role for neuronal membrane phospho-
lipids (‘lipid rafts’) in modulating AD-associated pathogen-
esis [5]. However, in animal models, apolipoprotein E
modulates the relationship between low-density lipoproteins
and amyloid-β (Aβ) deposition [6,7] suggesting an indirect
effect of intra-cranial cholesterol on Alzheimer’s pathology.
Furthermore, conflicting evidence from epidemiological
studies shows an unclear association between elevated chol-
esterol levels and AD risk [8,9], protein levels of fatty acid
binding proteins have been noted to be decreased in brains
of AD patients [10], and randomized clinical trials have
not shown a clear benefit of lipid-lowering therapy on AD
onset [2]. Thus there is a need for additional research eval-
uating the relationship between lipid biology and
neurodegeneration in individuals at risk for AD.
In humans, structural MRI and CSF biomarkers allow for
the indirect assessment of the cellular changes underlying
AD in vivo. Structural MRI provides measures of brain at-
rophy, which reflect loss of dendrites, synapses [11] and
neurons [12]. Low CSF levels of Aβ strongly correlate with
intracranial amyloid plaques and high concentrations of
CSF phospho-tau (p-tau) correlate with tau-associated
neurofibrillary tangles [13,14]. Recent work suggests that
CSF levels of heart fatty acid binding protein (HFABP or
FABP3), a lipid binding protein involved with fatty acid me-
tabolism and lipid transport [15] may have diagnostic and
prognostic value in the earliest stages of AD [16-20]. Here,
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among non-demented older individuals at risk for AD and
demented participants diagnosed with probable AD, we in-
vestigated whether CSF HFABP is associated with brain at-
rophy over time and whether interactions between high
CSF HFABP and low CSF Aβ1–42 and high CSF HFABP
and high CSF p-tau181p are associated with brain atrophy
over time. We also evaluated the relationship between CSF
HFABP and other lipid binding proteins including Apolipo-
protein (Apo) C III, Apo D, and Apo E.
Results
CSF HFABP and brain atrophy rates
In our initial analyses, we used linear mixed effects models,
co-varying for baseline age, sex, presence (“carriers”) or ab-
sence (“non-carriers”) of at least one ε4 allele of apolipopro-
tein E (APOE ε4), diagnostic status (AD vs mild cognitive
impairment (MCI) vs healthy elderly controls (HC)), and
disease severity (CDR-Sum of Boxes score at baseline) to
examine whether CSF HFABP levels are associated with
longitudinal atrophy of the entorhinal cortex and other
AD-vulnerable regions of interest (‘AD vulnerable ROI’ –
for additional details see Methods) (Figure 1). We found a
significant relationship between CSF HFABP, time, and at-
rophy rate of the entorhinal cortex (β-coefficient = −0.007,
standard error (SE) = 0.003, p-value = 0.013) and the
AD-vulnerable ROI (β-coefficient =−0.005, SE = 0.002,
p-value = 0.017), indicating increased volume loss with ele-
vated CSF HFABP levels.
CSF HFABP, CSF Aβ1–42, CSF p-tau181p, and brain
atrophy rates
Next, we asked whether statistical interactions between
CSF HFABP and CSF Aβ1–42 and between CSF HFABP
and CSF p-tau181p are associated with brain atrophy over
time. These linear mixed effects models included the
main and interactive effects of CSF HFABP, CSF Aβ1–42,
status and CSF p-tau181 status, and co-varied for the
demographic and clinical variables mentioned previously
(see Methods for further details on the model). Key re-
sults from these models are shown in Table 1.
As illustrated in Table 1, with the interaction terms of the
three CSF biomarkers in the model, the association of CSF
HFABP with brain atrophy over time was not significant.
However, there were significant interactive effects between
CSF HFABP x CSF Aβ1–42 status x time and CSF HFABP x
CSF p-tau181p status x time on atrophy of both the entorhi-
nal cortex and the AD-vulnerable ROI. The only CSF bio-
marker to show a significant association with atrophy over
time in the entorhinal cortex and AD-vulnerable ROI was
CSF p-tau181p. Of the co-variates, the interaction of time by
diagnostic status and APOE ε4 carrier status were signifi-
cant for both entorhinal cortex atrophy (diagnostic status x
time: β-coefficient =−0.007, SE = 0.002, p-value = 0.0005;
APOE ε4 carrier status x time (β-coefficient = −0.004, SE =
0.002, p-value = 0.03) and AD-vulnerable ROI atrophy
(diagnostic status x time: β-coefficient = −0.006, SE = 0.002,
p-value = 0.0003; APOE ε4 carrier status x time (β-coeffi-
cient = −0.003, SE = 0.001, p-value = 0.02). None of the
Figure 1 Three-dimensional representations of the neuroanatomic regions examined in the current study (only one hemisphere is
shown). All of the examined neocortical regions are illustrated in the lateral and medial views of the gray matter surface (top row). The two non-
neocortical regions (i.e., the hippocampus and amygdala) are illustrated in the coronal view of a T1-weighted MRI image (bottom row). Regions
illustrated in red constitute the ‘AD-vulnerable ROI’ (for further details please see manuscript text).
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other variables showed significant main or interactive
effects.
To further investigate the three-way interactions, we
performed follow-up analyses after stratifying on the
basis of CSF Aβ1–42 status (i.e. low and high status) and
CSF p-tau181p status (i.e. high and low status). We found
a significant CSF HFABP by time interaction on entorhi-
nal cortex and AD-vulnerable ROI atrophy rate only
among individuals with low CSF Aβ1–42 levels (Table 1,
Figure 2A) Among individuals with high CSF Aβ1–42
levels and high or low CSF p-tau181p levels, we found no
effect of CSF HFABP by time on brain atrophy (Table 1,
Figure 2A, 2B). This indicates elevated volume loss with
elevated CSF HFABP and low CSF Aβ1–42 irrespective of
CSF p-tau181p status.
We also evaluated whether interactions between high
CSF HFABP and low CSF Aβ1–42 and high CSF HFABP
and high CSF p-tau181p are associated with longitudinal
clinical decline as assessed with the Alzheimer’s Disease
Assessment Scale-cognitive subscale (ADAS-cog). In
these analyses, neither the interaction between CSF
HFABP, CSF Aβ1–42 status and time nor the interaction
between CSF HFABP, CSF p-tau181p status and time was
significantly associated with longitudinal change in
ADAS-cog (see Additional file 1).
CSF HFABP and other lipid binding proteins
We next used generalized linear models to investigate
the relationship between CSF HFABP and CSF p-tau181p,
and levels of other lipid binding proteins including Apo-
lipoprotein (Apo) C III, Apo D, and Apo E at baseline.
The relation of each of these apolipoproteins with CSF
HFABP was assessed in separate models; all models con-
trolled for age, sex, APOE ε4 carrier status, diagnostic
status, and CDR-Sum of Boxes score.
We found significant associations between CSF
HFABP and CSF p-tau181p (β-coefficient = 0.008, SE =
0.001, p-value = < 2.0 x 10-16), CSF levels of Apo C III
(β-coefficient = 0.29, SE = 0.07, p-value = 4.2 x 10-5),
ApoD (β-coefficient = 0.35, SE = 0.09, p-value = 2.8 x
10-4), and ApoE (β-coefficient = 0.86, SE = 0.12, p-value
= 2.9 x 10-16) (Figure 3).
Using the same linear mixed effects framework de-
scribed above, we additionally evaluated whether statis-
tical interactions between CSF HFABP and the other
lipid binding proteins are associated with brain atrophy
over time. We found a significant interaction only be-
tween CSF HFABP and CSF Apo C III on entorhinal
cortex atrophy rate (β-coefficient = 0.02, SE = 0.009, p-
value = 0.02). None of the other lipid binding proteins
demonstrated a significant interaction with CSF HFABP
on atrophy rates of the entorhinal cortex and the AD-
vulnerable ROI (p-values > 0.2).
Discussion
Here, we demonstrate that in non-demented older indi-
viduals at risk for AD and in mild AD participants,
HFABP is associated with volume loss in brain areas se-
lectively affected in the earliest stages of AD. However,
we found that the relationship between HFABP and
brain atrophy is present only among individuals with
low CSF Aβ1–42, and occurs irrespective of phospho-tau
levels. Considered together, these results suggest a po-
tentially important role for fatty acid binding proteins in
early Alzheimer’s disease pathobiology.
Our findings also indicate that rather than simply
representing a generalized marker of neuronal degener-
ation, elevated CSF levels of HFABP may reflect central
nervous system lipid dyshomeostasis. Consistent with
prior studies [16,18], we found a significant association
Table 1 Linear mixed effects model results for analyses involving all 295 participants
Main effect Interaction with time Interaction with HFABP and time
Entorhinal Cortex
CSF HFABP 0.005 (0.15) −0.005 (0.34) N/A
CSF Aβ1–42 status 0.003 (0.17) −0.0004 (0.88) −0.017 (0.003)
CSF p-tau181p status −0.004 (0.15) −0.01 (0.0007) 0.020 (0.0005)
AD-Vulnerable ROI
CSF HFABP 0.003 (0.21) −0.003 (0.51) N/A
CSF Aβ1–42 status 0.001 (0.44) −0.0000 (0.99) −0.013 (0.002)
CSF p-tau181p status −0.002 (0.10) −0.0007 (0.002) 0.014 (0.001)
Time by HFABP Entorhinal cortex Time by HFABP AD Vulnerable ROI
Low CSF Aβ1–42 (n = 211) −0.009 (0.007) −0.007 (0.007)
High CSF Aβ1–42 (n = 86) 0.001 (0.75) 0.003 (0.22)
High CSF p-tau181p (n = 197) −0.002 (0.58) −0.002 (0.47)
Low CSF p-tau181p (n = 98) −0.006 (0.21) −0.002 (0.35)
Beta-coefficients with p-values indicated in parenthesis. Please see text for additional details.
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Figure 2 (See legend on next page.)
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between HFABP and phospho-tau. However, we also
found a strong relationship between HFABP and a num-
ber of apolipoproteins including ApoE, as well as an
interaction between HFABP and ApoC III on volume
loss. Together, these findings support the hypothesis that
intra-cranial lipid biology may influence Alzheimer’s
neurodegeneration [5].
Our results suggest that the relationship between
neuronal lipid biology and neurodegeneration may be
influenced by amyloid pathology even after controlling
for the effects of APOE ε4. An important aspect of
our findings is the specific relationship between
HFABP and Aβ deposition, where volume loss occurs
only in the presence of elevated HFABP and de-
creased Aβ (i.e. increased Aβ deposition in the brain).
A growing body of experimental evidence from
various model systems indicates that phospholipids
play an integral role in regulating amyloidogenesis.
Enriched cholesterol and lipid microenvironments
(‘lipid rafts’) within the plasma membrane and the
(See figure on previous page.)
Figure 2 (A) Spaghetti plots illustrating atrophy of the entorhinal cortex among all participants classified as low Aβ1–42 and high
HFABP (based on median value of FABP) (top left panel), low Aβ1–42 and low HFABP (top right panel), high Aβ1–42 and high FABP
(bottom left panel), and high Aβ1–42 and low FABP (bottom right panel). The red line indicates the mean atrophy rate for the four
respective groups (i.e. low Aβ1–42 and high FABP, low Aβ1–42 and low FABP, high Aβ1–42 and high FABP and high Aβ1–42 and low FABP). As
illustrated, the slopes of the red lines are significantly different depending on CSF Aβ1–42 status (please see text for further details). (B) Spaghetti
plots illustrating atrophy of the entorhinal cortex among all participants classified as high p-tau181p and high HFABP (based on median value of
FABP) (top left panel), high p-tau181p and low HFABP (top right panel), low p-tau181p and high FABP (bottom left panel), and low p-tau181p and
low FABP (bottom right panel). The red line indicates the mean atrophy rate for the four respective groups (i.e. high p-tau181p and high FABP,
high p-tau181p and low FABP, low p-tau181p and high FABP and low p-tau181p and low FABP). As illustrated, the slopes of the red lines are not
significantly different depending on CSF p-tau181p status (please see text for further details).
Figure 3 Scatter plots demonstrating the relationship between baseline CSF levels of HFABP (quality-controlled, transformed values as
described in reference 18) CSF p-tau181p (top left), CSF ApoC III (top right), CSF ApoD (bottom left) and CSF ApoE (bottom right). The
black line represents the best-fit regression line.
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mitochondria-associated endoplasmic reticulum mem-
brane promote γ-secretase activity resulting in in-
creased Aβ production [5,21]. In comparison, outside
lipid rafts, amyloid-precursor protein (APP) process-
ing occurs predominantly via the non-amyloidogenic
α-secretase pathway [22]. Membrane phospholipids
also influence Aβ aggregation and clearance [5] and
through release of arachidonic acid via the phospho-
lipase 2 pathway, may additionally serve as critical
mediators in Aβ-induced synaptoxicity, leading to
learning, memory, and behavioral impairments in
mouse models of AD [23]. Our results are con-
sistent with these observations and suggest that phos-
pholipids and lipid binding proteins may affect
Alzheimer’s neurodegeneration primarily via Aβ-
associated mechanisms.
One potential concern is that our current findings
do not explain the previously noted relationships ob-
served between HFABP and non-AD neurodegenera-
tive diseases such as vascular dementia, Creutzfeldt-
Jakob disease, Parkinson’s disease, and dementia with
Lewy bodies [18,24-27]. Though we did not explicitly
evaluate the role of HFABP in other neurodegenera-
tive conditions or as a differential disease marker of
AD, our findings may help provide insights into com-
mon mechanisms underlying an array of protein
misfolding neurologic disorders. For example, lipid
metabolism may play an important role in synaptic
degeneration and regeneration [28] and as such, may
be involved in a number of neurodegenerative dis-
eases. Another intriguing notion is that in addition to
APP and Aβ, phospholipid rich lipid rafts may play
an important role in mediating pathogenesis associ-
ated with a number of proteins including α-synuclein
[29,30] and prions [31,32] thus raising the possibility
that lipid dyshomeostasis may represent an early
trigger for a number of protein misfolding neurode-
generative disorders.
A limitation of our study is its observational nature,
which precludes conclusions regarding causation. Our
results cannot differentiate whether elevated HFABP
causes, results from, or is simply correlated with
amyloid deposition and volume loss. Additionally, our
findings require further validation on a larger, inde-
pendent population-based cohort.
Conclusions
In summary, our results suggest that CSF HFABP re-
flects intra-cranial lipid biology and associates with Aβ-
associated neurodegeneration irrespective of tau. Clinic-
ally, our findings suggest that HFABP may represent an
important modifier of progression from amyloid depos-
ition to neurodegeneration. Considered together with
our prior findings [33,34], this suggests that in addition
to phospho-tau, the HFABP/Aβ/neurodegeneration axis
may represent an important area for further investiga-
tion. Using experimental models, it would be helpful to
better understand the precise relationship between
HFABP and Aβ dyshomeostasis and whether proteins in-
fluence or modulate this association. The results of these
studies could provide insights into whether fatty acids
and lipids represent a viable therapeutic target for indi-
viduals in the presymptomatic and very mildly symp-
tomatic phase of the disease process.
Methods
We evaluated cognitively normal older adults (HC= 90), in-
dividuals diagnosed with amnestic MCI (n = 139), and
probable AD (n = 66) from the Alzheimer’s Disease Neuro-
imaging Initiative (ADNI; see Additional file 1 for further
details). From a total of 415 demented and non-demented
older individuals who underwent longitudinal MR imaging
Table 2 Demographic, clinical, and imaging data for all participants in this study
HC (n = 90) MCI (n = 139) AD (n = 66)
Age, Mean (SE) 76.0 (0.6) 75.1 (0.7) 75.4 (0.9)
Female, % 51 33 41
Education Years, Mean (SE) 15.6 (0.3) 16.1 (0.2) 15.1 (0.4)
MMSE, Mean (SE) 29.1 (0.1) 26.7 (0.1) 23.4 (0.2)
CDR-SB, Mean (SE) 0.03 (0.01) 1.5 (0.07) 4.2 (0.2)
APOE ε4 carriers (%) 24 54 71
CSF H-FABP level (ng/ml), Mean (SE) 0.38 (0.03) 0.54 (0.02) 0.58 (0.03)
CSF Aβ1–42 level (pg/ml), Mean (SE) 207.8 (5.6) 157.5 (4.1) 141.5 (2.6)
CSF p-tau181p level (pg/ml), Mean (SE) 24.7 (1.4) 36.8 (1.3) 41.7 (2.6)
Entorhinal Cortex APC, Mean (SE) −0.8 (0.1) −2.4 (0.1) −2.9 (0.2)
AD-vulnerable ROI APC, Mean (SE) −1.1 (0.1) −3.2 (0.2) −3.9 (0.3)
MCI; mild cognitive impairment, HC; cognitively normal older adults, AD; Alzheimer’s disease, MMSE; Mini-mental status exam, CDR-SB; Clinical dementia rating-sum
of boxes score, APC; Annualized percent change, SE; Standard error of the mean.
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and CSF lumbar puncture, we restricted our analyses to
those participants with quality-assured baseline and at least
one follow-up MRI scan (Table 2).
We evaluated baseline CSF HFABP levels analyzed
using a multiplex-based immunoassay panel. This
immunoassay panel, based on Luminex xMAP im-
munoassay technology and developed by Rules Based
Medicine (MyriadMBM), measures a range of lipid,
inflammatory, metabolic, and other AD-relevant indi-
ces (for further details, please see reference 18). We
also examined baseline CSF Aβ1–42 and CSF p-tau181p
levels, determined using the AlzBio3 Luminex xMAP
immunoassay (Innogenetics, Ghent, Belgium). Using
previously proposed CSF cutoffs 19 we classified par-
ticipants based on low (<192 pg/ml) and high
(>192 pg/ml) Aβ1–42 levels and high (>23 pg/ml) and
low (<23 pg/ml) p-tau181p levels.
We examined 1205 T1-weighted MRI scans. We
performed quantitative volume and surface-based ana-
lysis of all baseline MRI scans using automated
region-of-interest (ROI) labeling techniques [35,36],
primarily focusing on the entorhinal cortex, a medial
temporal lobe region that is selectively affected in the
earliest stages of AD [37] (Figure 1). To additionally
investigate neuroanatomic regions that are involved in
the later stages of the disease process [37,38], and to
minimize multiple comparisons, we averaged longitudinal
volume change in the temporal pole, parahippocampal
gyrus, inferior temporal gyrus, banks of the superior tem-
poral sulcus, inferior parietal lobule, amygdala, and hippo-
campus to create an ‘AD-vulnerable’ ROI [33,34]
(Figure 1). Using an image-analysis method developed
within our laboratory [39], we assessed longitudinal sub-
regional change in gray matter volume (atrophy) on serial
MRI scans (see Additional file 1 for additional details).
For the primary analyses, we used linear mixed ef-
fects models to examine the associations of CSF
HFABP, CSF Aβ1–42 status, and CSF p-tau181p status
on atrophy rate of the entorhinal cortex, and of the
AD-vulnerable ROI. All analyses co-varied for the ef-
fects of the baseline age, sex, presence (“carriers”) or
absence (“non-carriers”) of at least one ε4 allele of
apolipoprotein E (APOE ε4), diagnostic status (AD vs
MCI vs HC), and disease severity (CDR-Sum of Boxes
score at baseline).
Specifically, our initial model was:
Δv ¼ b0 þ b1Δtþ b2CSF–HFABP Δt
þ covariates Δtþ e ð1Þ
Here, Δv is the entorhinal cortex or AD-vulnerable
ROI thickness change from baseline (millimeters3) and
Δt is the change in time from baseline MRI scan (years).
Next, investigated whether interactions of CSF
HFABP with CSF Aβ1–42 status, and CSF p-tau181p
status were significantly associated with atrophy over
time. Specifically:
Δv ¼ β0 þ β1Δtþ β2CSF–HFABP Δt
þ β3CSF–Ab1–42–status Δt
þ β4CSF–p‐tau181p–status Δt
þ β5 CSF–HFABP CSF–Ab1–42–status Δt½ 
þ β6 CSF–HFABP CSFp‐tau181p–status  Δt
 
þ covariates Δtþ e
ð2Þ
In both models, the main effects of all variables were
also included. For brevity, we focus above on the effects
of interest.
Additional file
Additional file 1: Methods and results.
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